Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL
Open Access
- 10 July 2008
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 23 (2), 400-402
- https://doi.org/10.1038/leu.2008.184
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphomaBlood, 2007
- CD4 T-Helper Responses to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large-Cell LymphomaCancer Research, 2007
- Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.Blood, 2006
- Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphomaLeukemia, 2005
- Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer ProgramLeukemia, 2003
- Anaplastic large cell lymphoma: pathological, molecular and clinical featuresBritish Journal of Haematology, 2001
- Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphomaBlood, 2000